314 related articles for article (PubMed ID: 25256963)
1. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
Alchalby H; Kröger N
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
[TBL] [Abstract][Full Text] [Related]
3. Managing patients with myelofibrosis and low platelet counts.
Al-Ali HK; Vannucchi AM
Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
[TBL] [Abstract][Full Text] [Related]
4. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
Shanavas M; Gupta V
Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
6. Myelofibrosis: to transplant or not to transplant?
Devlin R; Gupta V
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):543-551. PubMed ID: 27913527
[TBL] [Abstract][Full Text] [Related]
7. Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
Viswabandya A; Devlin R; Gupta V
Curr Hematol Malig Rep; 2016 Feb; 11(1):6-11. PubMed ID: 26659587
[TBL] [Abstract][Full Text] [Related]
8. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
Gupta V; Hari P; Hoffman R
Blood; 2012 Aug; 120(7):1367-79. PubMed ID: 22700718
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Shanavas M; Popat U; Michaelis LC; Fauble V; McLornan D; Klisovic R; Mascarenhas J; Tamari R; Arcasoy MO; Davies J; Gergis U; Ukaegbu OC; Kamble RT; Storring JM; Majhail NS; Romee R; Verstovsek S; Pagliuca A; Vasu S; Ernst B; Atenafu EG; Hanif A; Champlin R; Hari P; Gupta V
Biol Blood Marrow Transplant; 2016 Mar; 22(3):432-40. PubMed ID: 26493563
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.
Gupta V; Gotlib J; Radich JP; Kröger NM; Rondelli D; Verstovsek S; Deeg HJ
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1274-81. PubMed ID: 24680977
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem-cell transplantation for myelofibrosis.
Lavi N; Rowe JM; Zuckerman T
Curr Opin Hematol; 2017 Nov; 24(6):475-480. PubMed ID: 28832353
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.
Jaekel N; Behre G; Behning A; Wickenhauser C; Lange T; Niederwieser D; Al-Ali HK
Bone Marrow Transplant; 2014 Feb; 49(2):179-84. PubMed ID: 24292520
[TBL] [Abstract][Full Text] [Related]
14. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
El Fakih R; Popat U
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
[TBL] [Abstract][Full Text] [Related]
15. How I treat myelofibrosis.
Cervantes F
Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
[TBL] [Abstract][Full Text] [Related]
16. The future of JAK inhibition in myelofibrosis and beyond.
Mascarenhas JO; Cross NC; Mesa RA
Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
18. How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.
Polverelli N; Farina M; D'Adda M; Damiani E; Grazioli L; Leoni A; Malagola M; Bernardi S; Russo D
Cells; 2022 Feb; 11(3):. PubMed ID: 35159362
[TBL] [Abstract][Full Text] [Related]
19. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
Saeed I; McLornan D; Harrison CN
Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation for myelofibrosis in 2012.
McLornan DP; Mead AJ; Jackson G; Harrison CN
Br J Haematol; 2012 May; 157(4):413-25. PubMed ID: 22463701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
